James Reed, DO
Psychiatry · Sierra Vista, AZNPI 1790719441
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 270 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$776
- Vanda Pharmaceuticals Inc.$604
- Teva Pharmaceuticals USA, Inc.$600
- Supernus Pharmaceuticals, Inc.$568
- Otsuka America Pharmaceutical, Inc.$326
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,56297%
- Education$1583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $1,029 |
| Alkermes, Inc. | 34 | $776 |
| Vanda Pharmaceuticals Inc. | 31 | $604 |
| Teva Pharmaceuticals USA, Inc. | 19 | $600 |
| Supernus Pharmaceuticals, Inc. | 28 | $568 |
| Otsuka America Pharmaceutical, Inc. | 17 | $326 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $289 |
| Neurocrine Biosciences, Inc. | 10 | $252 |
| E.r. Squibb & Sons, L.L.C. | 5 | $203 |
| Lundbeck LLC | 9 | $161 |
| Sunovion Pharmaceuticals Inc. | 7 | $137 |
| Avanir Pharmaceuticals, Inc. | 8 | $132 |
| Johnson & Johnson | 5 | $109 |
| Ironshore Pharmaceuticals Inc. | 6 | $104 |
| Almatica Pharma LLC | 6 | $102 |
| Corium, LLC | 3 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $36 |
| Tris Pharma Inc | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$480
- ARISTADA INITIO$120
How this compares
$5,720 in reported general payments places this provider in the 90th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $209,146 |
| AplenzinBupropion Hbr | 12 | $69,120 |
| CaplytaLumateperone Tosylate | 24 | $44,002 |
| Tetrabenazine | 12 | $43,853 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $38,338 |
| TrintellixVortioxetine Hydrobromide | 29 | $19,656 |
| VraylarCariprazine Hcl | 14 | $19,517 |
| Wellbutrin SrBupropion Hcl | 16 | $10,615 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 154 | $5,289 |
| DayvigoLemborexant | 15 | $5,203 |
| Vilazodone Hcl | 47 | $4,630 |
| Aripiprazole | 35 | $4,366 |
| Duloxetine Hcl | 164 | $4,353 |
| Bupropion XlBupropion Hcl | 78 | $4,301 |
| Atomoxetine Hcl | 26 | $2,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $252 | $209,14627 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $289 | $44,00224 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $132 | $38,33823 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $55 | $19,65629 claims |
| AbbVieVraylar | $1,029 | $19,51714 claims |
| Eisai Inc.Dayvigo | $14 | $5,20315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Sierra Vista
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Bahar GolestanMesa$234K
- Eric ReimanPhoenix$157K
- Christopher LinskeyPage$100K
- Henry SchulteScottsdale$77K
- Marlene FreemanTucson$59K
- Lauren BonnerScottsdale$44K
- Padma AkingPhoenix$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.